In this study, 153 patients with AR who received SLIT with Dermatophagoides farinae (D. farinae) drops in the Otorhinolaryngology Department of Tianjin Children’s Hospital from January 2020 to October 2021 were selected as the study objects. The patient’s sex, age, serum vitamin D3 levels, family history of allergic disease, food allergies, their caregiver’s education level, asthma status, whether they had used acarid products, etc. were collected retrospectively. All patients included in this study recorded their visual simulation scores, symptom scores, medication scores, and quality of life scores to evaluate the efficacy of SLIT. The primary endpoint of this study was the efficacy of patients treated with SLIT, and the independent influencing factors affecting the efficacy of SLIT were analyzed.
The enrolled patients were required to fully meet the following conditions: (I) diagnosed with AR, with or without other allergic diseases; (II) 3–14 years old, male or female; (III) allergen detection results: dust mites were positive, closely related to clinical symptoms and were the main allergen; (IV) allergens could be avoided as much as possible during treatment; (V) willing to receive SLIT and able to comply with the program and receive follow-up. The exclusion criteria were as follows: (I) patients with infectious rhinitis; (II) patients who could not understand the purpose of this study and refused to cooperate with follow-up; (III) those with incomplete data. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). This study was approved by the Ethics Committee of Tianjin Children’s Hospital (No. KY2020-47) and informed consent was taken from all the patients’ guardians.
The enrolled patients were required to fully meet the following conditions: (I) diagnosed with AR, with or without other allergic diseases; (II) 3–14 years old, male or female; (III) allergen detection results: dust mites were positive, closely related to clinical symptoms and were the main allergen; (IV) allergens could be avoided as much as possible during treatment; (V) willing to receive SLIT and able to comply with the program and receive follow-up. The exclusion criteria were as follows: (I) patients with infectious rhinitis; (II) patients who could not understand the purpose of this study and refused to cooperate with follow-up; (III) those with incomplete data. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). This study was approved by the Ethics Committee of Tianjin Children’s Hospital (No. KY2020-47) and informed consent was taken from all the patients’ guardians.
